ProteoMediX: Funding, Investors & Team (Sep 2026)
ProteoMediX is a spinoff company of ETH Zurich and specialized in the identification of novel biomarkers for the early detection of cancer and the personalized treatment thereof.The first product currently developed is a blood-based test that enables the diagnosis of prostate cancer with significantly higher accuracy than today's clinical standard.This reduces unnecessary biopsies and thus results in significant cost savings for the healthcare system and less discomfort for the patient.
ProteoMediX has raised $3.2M across 1 funding round on record, the most recent a Debt Financing of $3.2M announced in Sep 2021.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
ProteoMediX Company Profile and Key Stats
Latest funding round on record: Sep 2021.
ProteoMediX Funding Rounds
ProteoMediX Founders and Leadership Team
Contact details for the ProteoMediX team: 1 of 1 has an email address on file.
Start 14-day free trial →ProteoMediX Funding Compared to Other Biotechnology Startups
ProteoMediX's latest round of $3.2M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ProteoMediX in Biotechnology and Schlieren
Companies Similar to ProteoMediX
Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…
At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful…
compliag is providing agile solutions for regulated industries, including the licencing, manufacturing and…
MoonLake Immunotherapeutics is a biopharmaceutical company in the clinical stage that is developing new…
Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are…
Cria Technologies reinvents cold-chain transport with high-vacuum insulation technology that offers…
Precise Health is a phage therapy platform that specialises in improving and treating bacterial infections to…
AC Immune is a biopharmaceutical company based in Switzerland that is currently in the clinical stage. They…
AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at…
Combioxin SA is clinical-stage biotech company developing innovative anti-virulence drugs to treat severe…
MindMaze is a digital neurotherapeutic platform that provides digital assessments and therapeutics to treat…
Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the…
ProteoMediX Funding FAQs
What does ProteoMediX do?
ProteoMediX is a spinoff company of ETH Zurich and specialized in the identification of novel biomarkers for the early detection of cancer and the personalized treatment thereof.The first product currently developed is a blood-based test that enables the diagnosis of prostate cancer with significantly higher accuracy than today's clinical standard.This reduces unnecessary biopsies and thus results in significant cost savings for the healthcare system and less discomfort for the patient.
How much funding has ProteoMediX raised?
ProteoMediX has raised $3.2M across 1 round on record. The most recent is a Debt Financing of $3.2M announced in Sep 2021.
When did ProteoMediX last raise funding?
ProteoMediX's most recent funding round on record is a Debt Financing of $3.2M, announced in Sep 2021.
Who is the CEO of ProteoMediX?
Helge Lubenow is listed as CEO at ProteoMediX.
Where is ProteoMediX headquartered?
ProteoMediX is based in Schlieren, Zurich, Switzerland.
How many employees does ProteoMediX have?
ProteoMediX is in the 1-10 employee band.
How does ProteoMediX's funding compare to other Biotechnology startups?
ProteoMediX's latest round of $3.2M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's ProteoMediX Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ProteoMediX is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.